The US Food and Drug Administration (FDA) has accepted Merck's New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar for standard review. Merck which is known as MSD outside the United States and Canada is seeking US FDA approval of vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack (TIA).

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.